Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 51, Issue 5, Pages 817-819Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2004.06.007
Keywords
-
Categories
Ask authors/readers for more resources
Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available